JP2022501383A5 - - Google Patents

Info

Publication number
JP2022501383A5
JP2022501383A5 JP2021515616A JP2021515616A JP2022501383A5 JP 2022501383 A5 JP2022501383 A5 JP 2022501383A5 JP 2021515616 A JP2021515616 A JP 2021515616A JP 2021515616 A JP2021515616 A JP 2021515616A JP 2022501383 A5 JP2022501383 A5 JP 2022501383A5
Authority
JP
Japan
Prior art keywords
cancer
composition according
prostate cancer
contrast agent
metastatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021515616A
Other languages
English (en)
Japanese (ja)
Other versions
JP7429688B2 (ja
JP2022501383A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/051903 external-priority patent/WO2020061293A1/en
Publication of JP2022501383A publication Critical patent/JP2022501383A/ja
Publication of JP2022501383A5 publication Critical patent/JP2022501383A5/ja
Priority to JP2023204832A priority Critical patent/JP7748438B2/ja
Application granted granted Critical
Publication of JP7429688B2 publication Critical patent/JP7429688B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021515616A 2018-09-21 2019-09-19 シールド剤およびそれらの使用 Active JP7429688B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023204832A JP7748438B2 (ja) 2018-09-21 2023-12-04 シールド剤およびそれらの使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862734690P 2018-09-21 2018-09-21
US62/734,690 2018-09-21
PCT/US2019/051903 WO2020061293A1 (en) 2018-09-21 2019-09-19 Shielding agents and their use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023204832A Division JP7748438B2 (ja) 2018-09-21 2023-12-04 シールド剤およびそれらの使用

Publications (3)

Publication Number Publication Date
JP2022501383A JP2022501383A (ja) 2022-01-06
JP2022501383A5 true JP2022501383A5 (cg-RX-API-DMAC7.html) 2022-09-29
JP7429688B2 JP7429688B2 (ja) 2024-02-08

Family

ID=69887812

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021515616A Active JP7429688B2 (ja) 2018-09-21 2019-09-19 シールド剤およびそれらの使用
JP2023204832A Active JP7748438B2 (ja) 2018-09-21 2023-12-04 シールド剤およびそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023204832A Active JP7748438B2 (ja) 2018-09-21 2023-12-04 シールド剤およびそれらの使用

Country Status (5)

Country Link
US (1) US20210323985A1 (cg-RX-API-DMAC7.html)
EP (1) EP3853213A4 (cg-RX-API-DMAC7.html)
JP (2) JP7429688B2 (cg-RX-API-DMAC7.html)
CN (1) CN113166087B (cg-RX-API-DMAC7.html)
WO (1) WO2020061293A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102318999B1 (ko) * 2012-11-15 2021-10-29 엔도사이트, 인코포레이티드 Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트
WO2015073678A1 (en) 2013-11-14 2015-05-21 Endocyte, Inc. Compounds for positron emission tomography
MX2020010813A (es) 2018-04-17 2021-01-08 Endocyte Inc Metodos de tratamiento de cancer.
EP3972627A4 (en) 2019-05-20 2023-06-21 Endocyte, Inc. Methods for preparing psma conjugates
WO2022106629A1 (en) 2020-11-19 2022-05-27 Novartis Ag Synthesis of prostate specific membrane antigen (psma) ligands
US20250332265A1 (en) * 2021-11-09 2025-10-30 Case Western Reserve University Psma targeted conjugate compounds and uses thereof
WO2026120497A1 (en) 2024-12-05 2026-06-11 Novartis Ag Stable radionuclide complex solutions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2684322T3 (es) * 2006-11-08 2018-10-02 Molecular Insight Pharmaceuticals, Inc. Heterodímeros de ácido glutámico
DK2187965T3 (da) 2007-08-17 2020-01-20 Purdue Research Foundation Psma-bindingsligand-linker-konjugater og fremgangsmåder til anvendelse
PL2721039T3 (pl) * 2011-06-15 2018-06-29 Cancer Targeted Technology Llc Chelatowane inhibitory PSMA
KR102318999B1 (ko) * 2012-11-15 2021-10-29 엔도사이트, 인코포레이티드 Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트
AU2014336638C1 (en) 2013-10-18 2020-09-17 Novartis Ag Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
ES2908411T3 (es) 2014-08-06 2022-04-29 Univ Johns Hopkins Profármacos del inhibidor del antígeno de membrana específico de la próstata (PSMA)
JP2017530109A (ja) * 2014-09-08 2017-10-12 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド 前立腺癌についてのpsmaを標的とした放射性核種治療中の臓器の保護
SG11201909513QA (en) * 2017-04-11 2019-11-28 Univ Johns Hopkins Prodrugs of 2-pmpa for healthy tissue protection during psma-targeted cancer imaging or radiotherapy

Similar Documents

Publication Publication Date Title
Kostos et al. AlphaBet: combination of radium-223 and [177Lu] Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol)
CN107382846B (zh) Psma-结合剂及其用途
Mathias et al. Synthesis of [99mTc] DTPA-folate and its evaluation as a folate-receptor-targeted radiopharmaceutical
Meredith et al. Phase II study of interferon-enhanced 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer
JP2021522193A5 (cg-RX-API-DMAC7.html)
Pfestroff et al. Current status and future perspectives of PSMA-targeted therapy in Europe: opportunity knocks
JP2020531463A5 (cg-RX-API-DMAC7.html)
JP2019527740A5 (cg-RX-API-DMAC7.html)
Illidge et al. Radioimmunotherapy in follicular lymphoma
Shinto et al. Clinical utility of 188Rhenium-hydroxyethylidene-1, 1-diphosphonate as a bone pain palliative in multiple malignancies
JP2024516359A5 (cg-RX-API-DMAC7.html)
El-Mabhouh et al. 188Re-labeled bisphosphonates as potential bifunctional agents for therapy in patients with bone metastases
Du et al. Preliminary evaluation of alpha-emitting radioembolization in animal models of hepatocellular carcinoma
US20210236664A1 (en) Alpha particle formulations for treatment of solid tumors
JP2006523664A5 (cg-RX-API-DMAC7.html)
JP2008533079A5 (cg-RX-API-DMAC7.html)
Kim et al. Preclinical evaluation of isostructural Tc-99m-and Re-188-folate-Gly-Gly-Cys-Glu for folate receptor-positive tumor targeting
Dallagi et al. Synthesis and Biodistribution of 1-[2-(cyclopentadienyltricarbonyltechnetium-99m)-2-oxo-ethoxy-phenyl]-1, 2-di-(p-hydroxyphenyl) but-1-ene for tumor imaging
JP7239662B2 (ja) 複合体、造影剤、及びcxcr4関連疾患を治療又は診断するための医薬品
Skóra et al. Effectiveness of radioisotope therapy in bone metastases, based on personal experience
JP2017514829A5 (cg-RX-API-DMAC7.html)
JP2025503096A5 (cg-RX-API-DMAC7.html)
JP2003512296A (ja) がんの治療における放射性シスプラチン
Shinto et al. Important clinical applications of 188Rhenium for radionuclide therapy
CN119874628B (zh) 一种含氮化合物及其制备方法与用途